Evaluation and invivo studies of solid lipid nano carrier mediated drug delivery system of perinodopril

Mahesh Pg; I. Somasundaram

doi:10.53730/ijhs.v6nS3.7894

Evaluation and invivo studies of solid lipid nano carrier mediated drug delivery system of perinodopril

https://doi.org/10.53730/ijhs.v6nS3.7894

Authors

Mahesh Pg
pgmahesh83@gmail.com
Research scholar, School of Pharmaceutical Sciences, Vels Institute of Science Technology and Advanced Studies, Pallavaram, Chennai 600117, Tamilnadu, India
I. Somasundaram Associate Professor, Department of Pharmaceutics, School of Pharmaceutical Sciences, Vels Institute of Science Technology and Advanced Studies, Pallavaram, Chennai 600117, Tamilnadu, India

Keywords:

perinodopril, antihypertensive, NLC, lipid nanoparticles, carriers

Abstract

High BP is one of the most predominant causes of heart diseases and cerebrovascular problems. Perinodopril is an ACE inhibitor that is a non sulfhydryl derivative that is used for the treatment of hypertension. To enhance the effect of the drug it was formulated into Lipid based nano carrier system (NLC) to improve the bioavailability and thereby the therapeutic potential. So the objective of the current work was to evaluate the NLC of perinodopril formulation and to evaluate the same. The invivo estimation of the activity was carried out on Albino wistar rats that are maintained under room conditions and the formulation was investigated for the Pharamcokinetic and pharmacodynamic paramteres in rat plasma. Also they were tested for their stability invitro. Results show that the nano particles measured as 0.207nm in size. The invitro drug release studies suggest that the formulations were releasing the drug in controlled fashion during 23 hrs. stability studies proves the drug is very stable in the formulation. With R2 = 0.9683, the in vitro-in vivo correlation research clearly shows good agreement between in vitro drug solubilization during lipolysis and in vivo drug absorption during pharmacokinetic studies.

Downloads

Download data is not yet available.

References

Basalious E, Shawky N, Badr-Eldin S. SNEDDS containing bioenhancers for improvement of dissolution and oral absorption of lacidipine. I: Development and optimization. Int J Pharm. 2010;391(1-2):203-211. doi:10.1016/j.ijpharm.2010.03.008

Beg S, Sharma G, Thanki K, Jain S, Katare O, Singh B. Positively charged self- nanoemulsifying oily formulations of olmesartan medoxomil: Systematic development, in vitro, ex vivo and in vivo evaluation. Int J Pharm. 2015;493(1-2):466-482. doi:10.1016/j.ijpharm.2015.07.048

Beg S, Swain S, Singh HP, Patra CN and Rao MB. Development, Optimization, and Characterization of Solid Self-Nanoemulsifying Drug Delivery Systems of Valsartan Using Porous Carriers. AAPS Pharm SciTech 2012;13(4):1416-1427.

A, Solinis MA, Rodriguez- Gascon A, Almeida AJ and Preat V. Nanostructured lipid carriers: Promising drug delivery systems for future clinics. Nanomed 2016;12:143-161.

Beveridge T, Gratwohl A and Michot F. Cyclosporine: pharmacokinetics after a single dose in man and serum levels after multiple dosing in recipients of allogenic bone-marrow grafts. CurrTher Res 1981;30:5-18.

BioLineRx to Develop and Commercialize Novel Peptide Drug Candidates Discovered by Compugen [Online]. Available from: http://www.biolinerx.com, 5:27, 14 Apr 2016.

Bruno BJ, Miller GD and Lim CS. Basic and recent advances in peptide and protein drug delivery. Therdeliv 2013;4(11):1443-67.

Carey RM and Padia RH. Angiotensin AT2 receptors: control of renal sodium excretion and blood pressure. Trends Endocrinol Metab 2008;19(3):84-87.

Christopher JHP, Natalie LT and William NC. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs 2007;7:231-248.11.

Chadha R, Bhandari S, Kataria D, Gupta S. Exploring Lecithin/Chitosan Nanoparticles of Ramipril for Improved Antihypertensive Efficacy. J Nanopharm Drug Deliv 2013;1(2):173-181. doi:10.1166/jnd.2013.1014.

Published

25-05-2022

How to Cite

Pg, M., & Somasundaram, I. (2022). Evaluation and invivo studies of solid lipid nano carrier mediated drug delivery system of perinodopril. International Journal of Health Sciences, 6(S3), 8000–8008. https://doi.org/10.53730/ijhs.v6nS3.7894

Download Citation

Issue

Vol. 6 No. S3 (2022)

Section

Peer Review Articles

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.

Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.

This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.